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Granulocytic sarcomas are rare tumors that can present in innumerous locations; thus there
is  very little clinical experience with these cases. Therefore there is no consensus on which
is  the best treatment for patients with this malignancy.
The authors present a case of a female with a granulocytic sarcoma of the breast andeywords:
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hloroma
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adiotherapy
review the literature for the role of radiotherapy in the management of this clinical entity.
©  2014 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All
rights reserved..  Introduction
ranulocytic sarcomas (GS) are rare manifestations of acute
yeloid leukemia (AML). They consist of immature myeloid
ells that proliferate producing a clinically evident tumor.1,2
hese normally occur associated with AML, nevertheless very
arely they might present as isolated malignancies.1,3
Isolated GS of the breast (i.e. without medullary evidence of
eukemia) are somewhat rare, and frequently associated with
 dismal prognosis prompting treatment optimization.3–5
In the following section a case of an isolated GS of the breast
s presented.∗ Corresponding author. Tel.: +351 916014768.
E-mail address: joanagorete@gmail.com (J. Gonc¸alves).
ttp://dx.doi.org/10.1016/j.rpor.2014.02.002
507-1367/© 2014 Greater Poland Cancer Centre. Published by Elsevier U2.  Case  report
Thirty-ﬁve years old female with no relevant medical history,
on auto-examination of the breasts found a tender nodule on
the left breast.
Physical examination revealed a 25 mm nodule on the
upper external quadrant of the left breast, without any other
relevant ﬁndings.
The patient was submitted to an ultrasonography and a
mammography. These showed a solid heterogeneous nodule,
measuring 19.5 mm × 22 mm × 21 mm on the upper external
quadrant of the left breast and a small lymph node on the
ipsilateral axilla.
A tru-cut biopsy of this lesion was performed. Pathological
analysis was inconclusive; however GS and myoﬁbroblastoma
were referred as the most likely diagnoses; lymphoma, carci-
noma and melanoma were excluded.
rban & Partner Sp. z o.o. All rights reserved.
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Therefore the patient underwent tumorectomy. The ﬁnal
histologic diagnosis was GS with the following immunopheno-
type: myeloperoxidase+ CD45+, CD68+, CD34+, CD31+, CD43+,
Cam 5.2−, CD117−,  CD3−, CD20−, TdT−, CD10−.
As part of the workup a bone marrow study was conducted,
it revealed a normocellular marrow with no excess of imma-
ture cells, some atypia and signs of dysmyelopoiesis.
The patient underwent chemotherapy treatment: induc-
tion with idarrubicin and cytarabine, followed by consolida-
tion with 4 cycles of cytarabine. There were complications
during the consolidation phase: febrile neutropenia, pul-
monary aspergillosis, pyelonephritis and severe enterocolitis
(with need for parenteral nutrition).
A post induction chemotherapy magnetic resonance (MRI)
showed persistent disease (Fig. 1)
Another MRI, performed after completion of the entire
chemotherapy regime, revealed a heterogeneous enhance-
ment with approximately 60 mm (Fig. 2)
On a follow-up MRI, 3 months post chemotherapy, there
was no evidence of disease.
After resolution of the adverse reactions, the patient under-
went radiotherapy (RT). Radiation was delivered to the left
breast with a 3D conformal (multi-leaf collimator) technique:
30 Gy in 2 Gy fractions (1 fraction per day, 5 days per week),
with 6 MV  photons, in a total of 21 days (Fig. 3). There were no
interruptions of the treatment or any severe reactions. By the
end of the treatment the patient had grade 2 dermatitis of the
breast skin (CTCAE v4.03).
Fig. 2 – Post chemotherapy MRI.Fig. 3 – RT dose distribution (color wash).
At 26 months follow-up the patient remains asymptomatic
and there is no evidence of relapse of the disease.
3.  Discussion
Granulocytic sarcomas, or chloromas, are rare solid tumors,
composed of immature myeloid cells, which occur in
extramedullary locations.1,2 This malignancy was ﬁrst
described by Allan Burns in 1811.6 It was not until 1853
that the term chloroma was coined by King A.7; it derives
from the Greek chloros,  meaning green, due to a green tint
that myeloperoxidase gives these cells. However, the pres-
ence, concentration, and oxidative status of this enzyme
vary among tumors, giving cells different colors, 30% are
white, grey or brown. Therefore the term Granulocytic Sar-
coma, introduced by Rappaport in 19668 is nowadays the
most used one. This initially referred only to tumors of gran-
ulocytic origin, as GS most frequently develop in patients
with AML.1,3 This association was ﬁrstly noted by Dock  and
Warthin in 1902.9 Nevertheless, it can also be associated
with chronic myeloid leukemia, myelodysplastic syndrome,
chronic idiopathic myeloﬁbrosis, hypereosinophilic syndrome
and polycythemia vera hence the current broader use of
the term granulocytic sarcoma.1,3,4,10,11 These tumors present
more frequently concomitantly or after the diagnosis of
AML, there are, however, some cases where GS antedates
AML.1–5,10–13
Some have argued that there is a slight male predomi-
nance, however many  series fail to show any difference in
gender.1–4,10,11 Age of incidence ranges from 2 to 81 years
(mean 33–48 years) depending on the series.1–3 In a large
autopsy series published by Liu et al. that comprised 338
cases of myeloid leukemia (both acute and chronic) of which
23 had GS, age at onset was the only factor with statistical
signiﬁcance, with younger patients having a higher risk of
developing GS (under 15 years-old 13.6%; 15–44 y 6.7%; 45–59 y
4.4%; 60 y 0%).11
Granulocytic sarcomas can virtually occur anywhere in
the body, however it more  frequently arises in the skin, sub-
periosteal bone (cranium, paranasal sinuses, sternum, ribs,
and vertebrae), soft tissues of the head and neck, orbit, cen-
tral nervous system and lymph nodes.1–4,10,11,13,14 The breast
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s a relatively rare site for this malignancy, with few cases
eported, due to its rarity it is often misdiagnosed as ﬁbroade-
oma, lymphoma, carcinoma and sarcoma.1,3,14,15
Diagnosis requires ﬁnding myeloid cells in the lesions.
orphologic characteristics can vary depending on matura-
ion degree (mature, immature or blastic) and special dyes
ight be necessary to make the diagnosis. Many  features
an aid in conﬁrming the diagnosis, such as: positivity for
hloro-acetate esterase, myeloperoxidase, CD34, CD43, CD117
nd CD68.2,14 Several genetic anomalies have been associ-
ted with GS, such as t(8;21) and inv(16), these result in
ML1/ETO (RUNX1/RUNX1T1) and CBF/MYH11 gene fusions
espectively.4,16,17
Clinically GS of the breast may present as a unilateral or
ilateral mass, usually without associated signs or symptoms
uch as retraction of the skin or mammillary discharge.15,18,19
Mammography and ultrasonography are unspeciﬁc exams.
n mammograms  lesions can be well circumscribed as well
s irregular and inﬁltrative.20–23 This is also noted on ultra-
onography, where lesions are usually hypoechoic.20,23 In
omputed tomography GS appear isodense to muscle.21 In MRI
esions are heterogeneous, hyperintense in T2, with homoge-
eous enhancement with contrast.23,24 MRI can be useful in
valuating response to chemotherapy, detecting residual dis-
ase or clinically undetectable relapses, which might allow for
n earlier start of treatment.24
Treatment modalities include surgical excision, RT and
hemotherapy.2,3,10,17 Despite systemic treatment usually
eing effective, RT has been gaining more  importance in
he management of this disease. There has even been a
eported case of a complete response of a breast GS (in a
ost AML  setting) treated exclusively with RT (with a dose of
4 Gy).22
In circumstances where GS, due to its localization,
emands a rapid symptomatic relief, or decompression of
 vital structure, RT or surgery should be done prior to
hemotherapy. However, there is no evidence that combined
herapy is superior to isolated chemotherapy.
Treatment recommendations are highly dependent on
esponse to chemotherapy and whether GS was an initial diag-
osis or if it developed in a relapse setting. Ideal timing and
reatment are still a dilemma.
Many  authors argue that RT is associated with a longer
isease free survival, others consider that it should be used
s a consolidation treatment in isolated GS, especially since
he effective dose is quite small. The area to be irradiated
nd associated toxicities are important factors to consider.13
T must always be considered when there is an incomplete
esponse to chemotherapy. As a palliative treatment option it
as excellent results in symptomatic relief.13
Granulocytic sarcoma is a radiation sensitive malignancy,
.e. responds to low doses.
In a study by Chak and colleagues, that analyzed pallia-
ive RT treatments to symptomatic lesions, it was reported
hat response to treatment was directly related to total dose,
ith calculated chances of complete response of 18 ± 9% foress than 10 Gy, 43 ± 11% for 10–19.99 Gy, 86 ± 14% for 20–29 Gy
nd 89 ± 10% for more  than 30 Gy.25 This led to a recommen-
ation of at least 30 Gy in 15 fractions over 3 weeks, when
hemotherapy is not effective.25therapy 1 9 ( 2 0 1 4 ) 343–346 345
More recently Bakst et al.13 have argued that the minimum
dose could be as low as 20 Gy and propose a 24 Gy in 12 frac-
tions treatment, which they report as effective and safe. They
have also suggested that target volume should include resid-
ual disease post chemotherapy with a 10–20 mm margin and
that treatment could be delivered with photons or electrons
(for superﬁcial lesions).13
However, doses ranging from 4 to 40 Gy have been reported.
Song et al.10 propose doses according to tumor size: more
than 25 Gy (or BED10 30 Gy) if the tumor is less than 10 cm2;
a larger dose if >6 cm or 30 cm2 or if the tumor is not located
in soft tissue. In palliative treatments a dose of at least 20 Gy
is suggested.10
Despite the fact that the beneﬁt of RT in global survival
is yet to be proven, this treatment can contribute to increase
disease free survival in isolated GS cases, especially those that
have a partial response to chemotherapy.13
There might be occasional long survivors; however progno-
sis is usually reserved.3,4 In a large series of 92 patients, 89.5%
of patients had died from the disease at a median follow-up
of 150 months.4 Relapses are more  often in the ﬁrst two  years,
therefore during this period a tight surveillance is recom-
mended. Long-term follow-up has shown that patients who
achieve complete response have long remission free periods,
and in some cases can potentially achieve cure.
4.  Conclusion
Granulocytic sarcoma of the breast is very rare and, like the
case presented, many  patients do not have systemic signs of
the malignancy. Imaging gives little help in distinguishing GS
from carcinoma or lymphoma. Histology plays a major role in
the diagnosis, but can sometimes be inconclusive, especially
in poorly differentiated tumors that mimic  other neoplasms.
It has been argued that RT might increase disease or
progression free survivals, however this remains unproven.
Radiotherapy can be considered essential when GS presents
isolated, when there is a partial response to chemotherapy,
when there is a relapse after allergenic transplant or as a pal-
liative treatment to rapidly relief symptoms. The proposed
dose ranges from 20 to 30 Gy, using a conventional fraction-
ation (2 Gy per fraction), which, in most cases, achieves disease
control with minimum morbidity.
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